KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,926 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 10,926 shares of KalVista Pharmaceuticals stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $292,598.28. Following the transaction, the chief executive officer owned 479,989 shares in the company, valued at approximately $12,854,105.42. This trade represents a 2.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Price Performance

Shares of KALV traded up $0.02 during trading hours on Tuesday, reaching $26.81. 8,068,030 shares of the stock traded hands, compared to its average volume of 7,414,539. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.83 and a 52-week high of $26.85. The company’s 50-day moving average price is $21.74 and its two-hundred day moving average price is $17.54. The company has a market cap of $1.43 billion, a P/E ratio of -7.75 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $39.17 million for the quarter, compared to the consensus estimate of $39.03 million. On average, analysts anticipate that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current year.

Analyst Ratings Changes

KALV has been the subject of several research reports. Leerink Partners downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Citizens Jmp lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. HC Wainwright lowered KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $37.00 to $27.00 in a research report on Friday, May 1st. Finally, Needham & Company LLC lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $30.60.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KALV. Tudor Investment Corp ET AL purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $24,360,000. Jefferies Financial Group Inc. purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $3,494,000. Blue Owl Capital Holdings LP purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $1,522,000. Hennion & Walsh Asset Management Inc. raised its position in shares of KalVista Pharmaceuticals by 93.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 341,819 shares of the specialty pharmaceutical company’s stock valued at $5,520,000 after buying an additional 165,236 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ raised its position in shares of KalVista Pharmaceuticals by 391.9% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock valued at $2,449,000 after buying an additional 160,128 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.